Agile Therapeutics, Inc. (AGRX) Receives Consensus Recommendation of “Buy” from Analysts
Agile Therapeutics, Inc. (NASDAQ:AGRX) has been assigned a consensus rating of “Buy” from the seven research firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $10.20.
Several equities research analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Agile Therapeutics in a report on Monday, October 2nd. Royal Bank Of Canada reiterated a “buy” rating and issued a $10.00 target price on shares of Agile Therapeutics in a report on Wednesday, October 18th. Noble Financial reiterated a “buy” rating on shares of Agile Therapeutics in a report on Sunday, July 30th. ValuEngine lowered shares of Agile Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Finally, Janney Montgomery Scott reiterated a “buy” rating and issued a $13.00 target price (down from $15.00) on shares of Agile Therapeutics in a report on Thursday, August 24th.
Agile Therapeutics (AGRX) opened at 4.88 on Thursday. The company’s market cap is $140.57 million. The firm has a 50 day moving average price of $4.40 and a 200 day moving average price of $3.85. Agile Therapeutics has a 12-month low of $1.82 and a 12-month high of $7.80.
Agile Therapeutics (NASDAQ:AGRX) last posted its earnings results on Friday, July 28th. The specialty pharmaceutical company reported ($0.26) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.28) by $0.02. During the same quarter last year, the business earned ($0.29) earnings per share. On average, analysts anticipate that Agile Therapeutics will post ($1.02) earnings per share for the current fiscal year.
In related news, Chairman Alfred Altomari acquired 10,000 shares of the company’s stock in a transaction that occurred on Friday, August 25th. The shares were acquired at an average cost of $3.34 per share, for a total transaction of $33,400.00. Following the completion of the acquisition, the chairman now directly owns 161,587 shares in the company, valued at approximately $539,700.58. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 3.50% of the company’s stock.
Large investors have recently modified their holdings of the stock. Royal Bank of Canada raised its holdings in shares of Agile Therapeutics by 608.0% during the second quarter. Royal Bank of Canada now owns 32,497 shares of the specialty pharmaceutical company’s stock worth $122,000 after acquiring an additional 27,907 shares during the period. Janney Montgomery Scott LLC acquired a new stake in shares of Agile Therapeutics during the second quarter worth $122,000. Susquehanna International Group LLP acquired a new stake in shares of Agile Therapeutics during the second quarter worth $205,000. LMR Partners LLP acquired a new stake in shares of Agile Therapeutics during the second quarter worth $211,000. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Agile Therapeutics during the second quarter worth $309,000. Institutional investors and hedge funds own 67.51% of the company’s stock.
WARNING: “Agile Therapeutics, Inc. (AGRX) Receives Consensus Recommendation of “Buy” from Analysts” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/26/agile-therapeutics-inc-agrx-receives-consensus-recommendation-of-buy-from-analysts.html.
Agile Therapeutics Company Profile
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.